351 related articles for article (PubMed ID: 29675979)
1. Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer.
Chen Z; Hu K; Feng L; Su R; Lai N; Yang Z; Kang S
Cancer Sci; 2018 Jun; 109(6):1753-1763. PubMed ID: 29675979
[TBL] [Abstract][Full Text] [Related]
2. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
3. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
4. [Soluble PD-1 over-expression enhances the anti-tumor effect of senescence tumor cell vaccine against breast cancer cell growth in tumor-bearing mice].
Chen Z; Lin H; Hu K; Su R; Lai N; Yang Z; Kang S
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jan; 38(1):20-26. PubMed ID: 33177023
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
6. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.
Liu C; Lu Z; Xie Y; Guo Q; Geng F; Sun B; Wu H; Yu B; Wu J; Zhang H; Yu X; Kong W
Immunol Lett; 2018 Aug; 200():33-42. PubMed ID: 29894719
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.
Van den Bergh JMJ; Smits ELJM; Berneman ZN; Hutten TJA; De Reu H; Van Tendeloo VFI; Dolstra H; Lion E; Hobo W
Cancer Immunol Res; 2017 Aug; 5(8):710-715. PubMed ID: 28637876
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
9. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
Front Immunol; 2022; 13():830606. PubMed ID: 35935985
[TBL] [Abstract][Full Text] [Related]
10. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
11. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice.
Ge Y; Xi H; Ju S; Zhang X
Cancer Lett; 2013 Aug; 336(2):253-9. PubMed ID: 23523609
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
Song MY; Park SH; Nam HJ; Choi DH; Sung YC
J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
15. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
[TBL] [Abstract][Full Text] [Related]
16. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
17. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
Zahm CD; Colluru VT; McNeel DG
Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
[TBL] [Abstract][Full Text] [Related]
19. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
20. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
Mkrtichyan M; Najjar YG; Raulfs EC; Liu L; Langerman S; Guittard G; Ozbun L; Khleif SN
J Immunol; 2012 Sep; 189(5):2338-47. PubMed ID: 22837483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
